Goldspire™ 平台广泛适用于实体瘤的治疗。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2024-09-28 DOI:10.1016/j.clim.2024.110373

Jenny Zilberberg , Christopher Uhl , Charles B. Scott , David W. Andrews , Mark A. Exley

{"title":"Goldspire™ 平台广泛适用于实体瘤的治疗。","authors":"Jenny Zilberberg , Christopher Uhl , Charles B. Scott , David W. Andrews , Mark A. Exley","doi":"10.1016/j.clim.2024.110373","DOIUrl":null,"url":null,"abstract":"<div><div>Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5–6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (<span><span>NCT02507583</span><svg><path></path></svg></span>). A Phase 2b study (<span><span>NCT04485949</span><svg><path></path></svg></span>) recently completed enrollment.</div><div>Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"268 ","pages":"Article 110373"},"PeriodicalIF":4.5000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Broad applicability of the Goldspire™ platform for the treatment of solid tumors\",\"authors\":\"Jenny Zilberberg , Christopher Uhl , Charles B. Scott , David W. Andrews , Mark A. Exley\",\"doi\":\"10.1016/j.clim.2024.110373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5–6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (<span><span>NCT02507583</span><svg><path></path></svg></span>). A Phase 2b study (<span><span>NCT04485949</span><svg><path></path></svg></span>) recently completed enrollment.</div><div>Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells.</div></div>\",\"PeriodicalId\":10392,\"journal\":{\"name\":\"Clinical immunology\",\"volume\":\"268 \",\"pages\":\"Article 110373\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521661624004820\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521661624004820","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Goldspire™ 是一种个性化免疫疗法平台，它将整个肿瘤衍生细胞与生物扩散室（BDC；孔径 0.1 μm）中针对胰岛素样生长因子-1 受体（IGF-1R）的反义寡核苷酸（IMV-001）结合在一起。BDCs暴露于5-6Gy，并在腹部部位植入约48小时，以传递抗原载荷和免疫刺激因子来训练免疫系统。主导产品IGV-001在新诊断胶质母细胞瘤（ndGBM）患者中进行了1a和1b期试验评估（NCT02507583）。一项 2b 期研究（NCT04485949）最近完成了入组。在膀胱癌、胰腺癌、卵巢癌、结肠直肠癌或肾癌小鼠中，使用 Goldspire 生产的肿瘤特异性产品进行预防性治疗可限制肿瘤进展并延长总生存期。抗-PD-1可增强这种免疫疗法的疗效；在原位癌和黑色素瘤模型中，联合疗法优于单一疗法。最后，Goldspire 在与匹配的免疫细胞共同培养的过程中，激发了针对患者子宫内膜肿瘤衍生产物的免疫 T 细胞活化和记忆表型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Broad applicability of the Goldspire™ platform for the treatment of solid tumors

查看原文本刊更多论文

Broad applicability of the Goldspire™ platform for the treatment of solid tumors

Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5–6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (NCT02507583). A Phase 2b study (NCT04485949) recently completed enrollment.

Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.